ELISA/assay

KRIBIOLISA™ Anti-Tremilimumab ELISA

KBI2090

1 x 96 wells

660 USD

KRIBIOLISA™ Anti-Tremilimumab ELISA

ELISA

1 x 96 wells

660 USD

Enzyme Immunoassay for quantitative detection of anti-Tremilimumab antibodies in serum and plasma. About the kit: - Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity. - Recovery rates are between 85 - 115% - Ready to use with a standard protocol with break-apart pre-coated wells - Validated as per US FDA guidelines for Bioassays - Optimized for matrix effects to ensure higher sensitivity. - Shelf life: 1 year The method employs enzyme linked immunoassay technique. Standard or samples are pipetted into microwells pre-coated with the drug and anti-drug antibodies present in the sample and standards are bound by the drug. In the second step, HRP conjugate is pipetted and incubated. Free HRP conjugate will be removed by washing. Addition of TMB substrate will develop blue color and and reaction is stopped by addition of stop solution. Colour of the solution turns yellow. Intensity of yellow colour in wells is directly proportional to the concentration of anti-drug antibodies present in Standard or sample. Absorbance is measured at 450 nm.

Human

A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab-actl binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.Anti-Tremilimumab ELISA for the quantitative estimation of antibodies to Tremilimumab in human serum and plasma. Ready to Use Anti-Drug Antibody Assay.

This ELISA kit comes with a pre-coated plate, concentrated or lyophilized standards, wash solution, subtrate, stop solution and all the required diluents. For the exact contents of the kit, please refer to the datasheet / IFU.

2-8 Deg C

10 ng/ml - 640 ng/ml

8.75 ng/ml

The method employs the quantitative sandwich enzyme immunoassay technique. Tremilimumab is pre-coated onto microwells. Samples and standards are pipetted into microwells and antibodies to Tremilimumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated Tremilimumab is pipetted and incubated. After washing microwells in order to remove any nonspecific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Anti-Tremilimumab antibodies in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.

Anti-Tremilimumab Antibodies

RUO

2-8 degrees C